USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: COGNOSCI, INC.
City: RESEARCH TRIANGLE PARK
State: NC
Zip+4: 27709-2076
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $5,707,073.00 24
SBIR Phase II $8,209,142.00 6
STTR Phase I $714,377.00 3

Award List:

IMPROVED ASSAYS FOR SPECIFICALLY MEASURING COLLAGENASE-3

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael P. Vitek
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): The matrix metalloproteinases (MMPs) are associated with, and may be predictors of diseases such as osteoarthritis (OA), rheumatoid arthritis (RA), and cancer. In Phase I, we discovered novel and selective substrates for the MMP collagenase 3, an enzyme… More

IMPROVED ASSAYS FOR SPECIFICALLY MEASURING COLLAGENASE-3

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael P. Vitek
Award Amount: $1,412,986.00
Abstract:
DESCRIPTION (provided by applicant): The matrix metalloproteinases (MMPs) are associated with, and may be predictors of diseases such as osteoarthritis (OA), rheumatoid arthritis (RA), and cancer. In Phase I, we discovered novel and selective substrates for the MMP collagenase 3, an enzyme… More

IDENTIFICATION OF NEUROPROTECTIVE APOE-MIMETICS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael P. Vitek
Award Amount: $0.00
Abstract:
Not Avaialble

IDENTIFICATION OF NEUROPROTECTIVE APOE-MIMETICS

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael P. Vitek
Award Amount: $1,456,765.00
Abstract:
Not Avaialble

NEUROPROTECTIVE APOLIPOPROTEIN-E ANALOGS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael P. Vitek
Award Amount: $201,831.00
Abstract:
DESCRIPTION (provided by applicant): Apolipoprotein E (apoE) is a 299 amino acid protein that plays a palliative role in the CNS response to acute and chronic injury. We have recently demonstrated that the addition of exogenous apoE, or peptides derived from its receptor-binding domain, can reduce… More

NOVEL INHIBITORS OF BRAIN ISCHEMIA

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael P. Vitek
Award Amount: $284,008.00
Abstract:
DESCRIPTION (provided by applicant): Stroke is a leading cause of death and disability in the United States affecting approximately 750,000 individuals each year. Stroke is characterized by a partial or complete lack of blood flow to a region of the brain that becomes deprived of both oxygen and… More

INHIBITION OF CPB-MEDIATED NEUROLOGICAL DYSFUNCTION

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Suzanne E. Mckenna
Award Amount: $214,573.00
Abstract:
DESCRIPTION (provided by applicant): Cerebral injury remains one of the most frequent and devastating complications of heart surgery, for which there is no known therapy. These injuries, ranging from stroke to cognitive dysfunction, are a long-term problem for a substantial percentage of patients… More

ENHANCING PEPTIDE DELIVERY TO THE BRAIN

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Suzanne E. Mckenna
Award Amount: $265,517.00
Abstract:
DESCRIPTION (provided by applicant): There are currently 5.3 million Americans living with a disability as a result of a TBI, at a cost of $48.3 billion annually. The economic and social burden on the patient, their family, and society, is staggering and there is currently no effective treatment for… More

ENHANCING PEPTIDE DELIVERY TO THE BRAIN

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Suzanne E. Mckenna
Award Amount: $1,086,492.00
Abstract:
DESCRIPTION (provided by applicant): Traumatic brain injury (TBI) is the leading cause of death and disability in the US with an incidence rate of 1.5 million at cost of $56.3 billion annually. There is no treatment for TBI, and the lack of therapeutic intervention for a public health issue of this… More

Novel Anti-Inflammatory To Treat Atherosclerosis

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul J. Borron
Award Amount: $286,564.00
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular and cerebrovascular diseases including coronary artery disease (CAD), peripheral artery disease (PAD), heart attack, ischemic stroke, and transient ischemic attack (TIA), are the number one cause of mortality in the Western world and have a common… More

Novel Tissue Protector for Subarachnoid Hemorrhage

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: DUKE UNIVERSITY
Principal Investigator: Suzanne E. Mckenna
Award Amount: $171,707.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): There are approximately 30,000 new cases of aneurysmal subarachnoid hemorrhage (SAH) in this country, making it a significant health care problem. Despite advances in the medical and surgical care of patients with SAH, this condition still has a high morbidity… More

Novel Immunological Modifier to Treat Arthritic Disease

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul J. Borron
Award Amount: $211,523.00
Abstract:
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease targeting the synovium, the tissue that lines bone joints, and is associated with increased risk of infection, osteoporosis, and cardiovascular disease. RA causes pain and swelling,… More

Novel Restorative Therapy For Spinal Cord Injury

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Fengqiao Li
Award Amount: $305,045.00
Abstract:
DESCRIPTION (provided by applicant): This proposal responds to the solicitation of SBIR/STTR PHS 2006-2 for "Develop new preclinical testing for promising therapies for acute and chronic central nervous system injury" by NINDS. Spinal cord injury (SCI) is a devastating traumatic CNS disorder… More

Novel Immunological Modifer as a Tissue Protector

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael P. Vitek
Award Amount: $127,408.00
Abstract:
DESCRIPTION (provided by applicant): Novel Immunological Modifier as a Tissue Protector Tissues in the body can be damaged by a wide variety of events. Protecting these tissues after the damaging stimulus has been applied is a worthy goal. Several reports in the literature have shown that mice… More

Novel therapy for multiple sclerosis

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Fengqiao Li
Award Amount: $248,851.00
Abstract:
DESCRIPTION (provided by applicant): This proposal responds to the solicitation of SBIR/STTR PHS 2005-2 for "development of therapies to prevent, arrest or reverse autoimmune neurological disorder such as multiple sclerosis" by NINDS. Multiple sclerosis (MS) is a chronic inflammatory autoimmune… More

Novel Intervention for Amyloid-Induced Neuroinflammation

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: STONY BROOK UNIVERSITY
Principal Investigator: Michael P. Vitek
Award Amount: $263,420.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Novel Intervention for Amyloid-Induced Neuroinflammation Extracellular deposition of the amyloid a-protein (Aa) in brain is a prominent pathological feature of Alzheimer's disease (AD) and related disorders. Fibrillar A a deposition in the cerebral vasculature, a… More

Novel Intervention for Colitis

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: VANDERBILT UNIVERSITY MEDICAL
Principal Investigator: Michael P. Vitek
Award Amount: $279,250.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Novel Intervention for Colitis The scope of the current proposal is to determine whether administration of an apoE mimetic peptide, COG112, improves clinical, histological and inflammatory outcomes in clinically relevan t paradigms of colitis. Specifically, we… More

Novel Treatment for Parkinson's Disease

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dale J. Christensen
Award Amount: $290,289.00
Abstract:
DESCRIPTION (provided by applicant): Parkinson's Disease (PD) is a devastating neurodegenerative disorder that affects approximately 500,000 people in the US and an additional 50,000 are diagnosed each year. This disease is characterized by tremors in the limbs, bradykinesia, akinesia, rigid limbs,… More

Novel Therapy for Sepsis

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dale J. Christensen
Award Amount: $231,235.00
Abstract:
DESCRIPTION (provided by applicant): Sepsis remains an important medical problem that results in over 200,000 deaths each year in the United States. Sepsis syndrome results in multisystem organ failure due to a systemic inflammatory response and activation of the blood clotting cascade. Efforts to… More

Development of Remyelinating Agents

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Fengqiao Li
Award Amount: $286,509.00
Abstract:
DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is one of the devastating neurological diseases in young adults that is pathologically characterized by inflammation and demyelination in the brain and spinal cord. More than half of MS patients do not respond well to the current… More

Novel Therapy for Multiple Sclerosis (SBIR-Phase II)

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Fengqiao Li
Award Amount: $427,361.00
Abstract:
DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a devastating inflammatory and neurodegenerative disorder of the central nervous system (CNS). Currently, there are no effective treatments for Primary Progressive forms of MS (PP-MS) and more than half of Relapsing Remitting forms of… More

Neuroprotective Apolipoprotein-E Analogs Continuation

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael P. Vitek
Award Amount: $2,609,101.00
Abstract:
DESCRIPTION (provided by applicant): In our previous grants, we have developed COG1410, a novel anti-inflammatory peptide with additional neuroprotective properties, for the treatment of Traumatic Brain Injury (TBI). Each year, TBI accounts for 50,000 deat hs in the United States and of the… More

Novel Therapeutic for SAH

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dale J. Christensen
Award Amount: $249,686.00
Abstract:
DESCRIPTION: Subarachnoid Hemorrhage (SAH) is a form of stroke that occurs in nearly 40,000 patients each year in the United States. Despite advances in early diagnosis and management, SAH remains a frequent cause of death and disability. In particular, va sospasm is the most common medical… More

Novel Targeted Therapy for CLL

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dale J. Christensen
Award Amount: $257,133.00
Abstract:
DESCRIPTION (provided by applicant): Of the nearly 84,000 cases of leukemia in the Western world, B-cell chronic lymphocytic leukemia (B-CLL) is the most common and accounts for approximately 30% of all adult leukemia cases. It is characterized by the rele ntless accumulation of monoclonal mature B… More

Therapeutic for Intracerebral Hemorrhage

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dale J. Christensen
Award Amount: $258,584.00
Abstract:
DESCRIPTION (provided by applicant): Intracerebral hemorrhage (ICH) is a devastating and relatively common disease affecting as many as 50,000 people annually in the United States alone. ICH remains associated with poor outcome, and approximately 40 to 50 % of afflicted patients will die within 30… More

Novel Restorative Therapy for Spinal Cord Injury

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Fengqiao Li
Award Amount: $1,216,437.00
Abstract:
DESCRIPTION (provided by applicant): Novel Restorative Therapy for Spinal Cord Injury Spinal cord injury (SCI) is a devastating traumatic CNS disorder that significantly disables about 253,000 Americans where two-thirds of the new victims are under the age of 30. Functional deficits following SCI… More

Neurorestorative Strategy for Chemotherapy-induced Peripheral Neuropathy

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Fengqiao Li
Award Amount: $326,711.00
Abstract:
DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many commonly used chemotherapeutic agents, including platinum drugs and taxanes. CIPN, characterized by peripheral axonal degene ration and demyelination, can be disabling… More

Novel Screen for Targeted CLL Therapeutics

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dale J. Christensen
Award Amount: $289,114.00
Abstract:
DESCRIPTION (provided by applicant): Of the nearly 84,000 cases of leukemia in the Western world, B-cell chronic lymphocytic leukemia (B-CLL) is the most common and accounts for approximately 30% of all adult leukemia cases. It is characterized by the rele ntless accumulation of monoclonal mature B… More

High Throughput Screen for Novel Anti-Rheumatic Compounds

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dale J. Christensen
Award Amount: $333,305.00
Abstract:
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease targeting the synovium, the tissue that lines the joints. It is associated with increased risk of infection (pulmonary in particular) , osteoporosis, and cardiovascular disease.… More

Sustained Release Formulation for Treatment of Autoimmune Disease MS

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Feng-qiao Li – 919-765-0028
Award Amount: $279,054.00
Abstract:
DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is an inflammatory autoimmune disease in young adults, affecting more than 530,000 people in the United States and approximately 2 million worldwide. MS is characterized pathologically by inflammation, demyelination and axonal damage in… More

Novel COG Compounds to Treat Asthma

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael P. Vitek – 919-765-0028
Award Amount: $261,824.00
Abstract:
DESCRIPTION (provided by applicant): Our overall goal is to market a COG compound (aka. apoE-mimetic peptides) for the treatment of patients with asthma. Cognosci has discovered, patented and published a novel series of COG compounds which are functionalmimetics of apolipoprotein-E. These COG… More

Novel Drug VS-105 for Treatment of Osteoporosis

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael P. Vitek – 919-765-0028
Award Amount: $273,242.00
Abstract:
DESCRIPTION (provided by applicant): Investigational Safety and Toxicity Studies of Subcutaneous COG1410 for Alzheimer's Disease: A Therapeutic Based upon Apolipoprotein-E That is Not Targeted to Amyloid-Beta Background on Alzheimer's Disease: Alzheimer'sDisease (AD) is the leading… More

CDX-301 and Plerixafor Combination in Stem Cell Mobilization for Transplantation

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Feng-qiao Li – 919-765-0028
Award Amount: $225,067.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic peripheral neuropathy (DPN) is one of the most common and devastating complications of diabetes mellitus, affecting more than 50% of diabetic patients, and is the leading cause of foot amputation. DPN, characterized by peripheral axonal degeneration and… More